Serum IP-10/CXCL10 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.
Yoshihito NaguraTakanori SuzukiKentaro MatsuuraShintaro OgawaHayato KawamuraKayoko KunoKei FujiwaraShunsuke NojiriKatsuya NagaokaEtsuko IioTakehisa WatanabeHiromi KataokaYasuhito TanakaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Serum IP-10 change from baseline to 24 weeks after the EOT is a feasible predictor of regression of M2BPGi-based liver fibrosis after achieving SVR with DAA therapy. This article is protected by copyright. All rights reserved.